EU-UK trade deal continues to hurt trade with 27% drop in exports since 2021 reports Aston University
UK’s post-Brexit checks on fruit and vegetables delayed for a third time
Here’s Peter Foster, the FT’s public policy editor, on today’s UK-EU trade report:
Today’s report into UK-EU trade shows how Britain’s pharmaceuticals industry has suffered from regulatory divergence issues since Brexit.
For instance, while the mutual recognition of production certificates is agreed in the TCA [the Trade and Cooperation Agreement, or Brexit deal], the EU no longer recognises medicine batches tested in the UK as valid for sale within the single market, nor does it recognise the professionals overseeing these processes.
UK pharmaceutical firms now require separate certifications for both the UK and EU markets, resulting in increased costs and delays.
About Author
More Stories
Trump nominates Miami-Dade official as Panama ambassador amid canal row
Albania bans TikTok for a year after fatal stabbing of teenager last month
ECB faces tough task after flip in fortunes for eurozone economies